初次MRI引导穿刺阴性后前列腺癌风险
本研究纳入733例初次MRI引导穿刺阴性且因持续怀疑临床显著前列腺癌而接受重复MRI引导穿刺的男性。中位随访2.4年,17/73(23%)检出临床显著前列腺癌;随访MRI有病灶(PI-RADS≥3)者检出率为32%,无病灶者为0%(p<0.01)。结论认为初次阴性后随访MRI无病灶者可能避免重复穿刺,有病灶者应重复穿刺。
要点
- 初次MRI引导穿刺阴性后,随访MRI无病灶(PI-RADS<3)者未检出临床显著前列腺癌。
- 随访MRI有病灶(PI-RADS≥3)者临床显著前列腺癌检出率为32%。
- 随访MRI PI-RADS 5者中54%检出临床显著前列腺癌。
核心结论
- 初次MRI引导穿刺阴性后随访MRI无病灶者不太可能检出临床显著前列腺癌,或可避免重复穿刺。
- 随访MRI发现病灶(PI-RADS≥3)时,重复MRI引导穿刺是必要的。
研究设计与样本
- 回顾性研究,纳入2009年9月至2019年7月初次MRI引导穿刺阴性、因持续临床怀疑临床显著前列腺癌而接受至少1次重复MRI引导穿刺的男性。
- 研究对象为73/733例初次阴性者;穿刺方式为MRI-超声融合,包含靶向和系统穿刺。
- 主要终点为检出临床显著前列腺癌(Gleason分级分组≥2)。
主要发现
- 73例中17例(23%)在重复MRI引导穿刺时检出临床显著前列腺癌,中位随访2.4年(IQR 1.3-3.6)。
- 随访MRI有病灶(PI-RADS≥3)者中17/53(32%)检出临床显著前列腺癌;无病灶(PI-RADS<3)者0/20检出(p<0.01)。
- 随访MRI PI-RADS 5者中54%检出临床显著前列腺癌。
关键数值与推荐
- 临床显著前列腺癌定义为Gleason分级分组≥2。
- 重复MRI引导穿刺时随访MRI无病灶(PI-RADS<3)者未检出临床显著前列腺癌(0/20),有病灶者检出率32%(17/53),差异p<0.01。
临床怎么用
- 对初次MRI引导穿刺阴性者,可依据随访MRI表现决策是否重复穿刺:无病灶(PI-RADS<3)者可考虑避免重复穿刺。
- 随访MRI发现病灶(PI-RADS≥3)者应行重复MRI引导穿刺。
局限性
- 仅73/733例初次阴性者接受了重复MRI引导穿刺,存在选择偏倚可能。
- 随访组织学确认的报道较少,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Magnetic resonance imaging guided biopsy which reveals no cancer may impart reassurance beyond that offered by ultrasound guided biopsy. However, followup of men after a negative magnetic resonance imaging guided biopsy has been mostly by prostate specific antigen testing and reports of followup tissue confirmation are few. We investigated the incidence of clinically significant prostate cancer in such men who, because of persistent cancer suspicion, subsequently underwent a repeat magnetic resonance imaging guided biopsy. MATERIALS AND METHODS: Subjects were all men with a negative initial magnetic resonance imaging guided biopsy who underwent at least 1 further magnetic resonance imaging guided biopsy due to continued clinical suspicion of clinically significant prostate cancer (September 2009 to July 2019). Biopsies were magnetic resonance imaging-ultrasound fusion with targeted and systematic cores. Regions of interest from initial magnetic resonance imaging and any new regions of interest at followup magnetic resonance imaging guided biopsy were targeted. The primary end point was detection of clinically significant prostate cancer (Gleason Grade Group 2 or greater). RESULTS: Of 2,716 men 733 had a negative initial magnetic resonance imaging guided biopsy. Study subjects were 73/733 who underwent followup magnetic resonance imaging guided biopsy. Median (IQR) age and prostate specific antigen density were 64 years (59-67) and 0.12 ng/ml/cc (0.08-0.17), respectively. Baseline PI-RADS® scores were 3 or greater in 74%. At followup magnetic resonance imaging guided biopsy (median 2.4 years, IQR 1.3-3.6), 17/73 (23%) were diagnosed with clinically significant prostate cancer. When followup magnetic resonance imaging revealed a lesion (PI-RADS 3 or greater), clinically significant prostate cancer was found in 17/53 (32%). When followup magnetic resonance imaging was negative (PI-RADS less than 3), cancer was not found (0/20) (p <0.01). Overall 54% of men with PI-RADS 5 at followup magnetic resonance imaging guided biopsy were found to have clinically significant prostate cancer. CONCLUSIONS: Men with negative magnetic resonance imaging following an initial negative magnetic resonance imaging guided biopsy are unlikely to harbor clinically significant prostate cancer and may avoid repeat biopsy. However, when lesions are seen on followup magnetic resonance imaging, repeat magnetic resonance imaging guided biopsy is warranted.
引用
- Kinnaird A, Sharma V, Chuang R, et al. Risk of Prostate Cancer after a Negative Magnetic Resonance Imaging Guided Biopsy. J Urol. 2020. PMID: 32614257. doi:10.1097/JU.0000000000001232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。